SCHEMBL28537210

SCHEMBL28537210

CCOC(=O)COc1cc2nccc(Oc3ncc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c2cc1C(=O)NC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 0.66
MERTK Q12866 9/20 0.63
MET P08581 9/20 0.63
KDR P35968 2/20 0.56
AURKA O14965 1/20 0.56
RIPK2 O43353 1/20 0.56
ABCB11 O95342 1/20 0.56
ABL1 P00519 1/20 0.56
EGFR P00533 1/20 0.56
ERBB2 P04626 1/20 0.56
NTRK1 P04629 1/20 0.56
LCK P06239 1/20 0.56
PGR P06401 1/20 0.56
LYN P07948 1/20 0.56
RET P07949 1/20 0.56
CHRM2 P08172 1/20 0.56
HCK P08631 1/20 0.56
ADRA2A P08913 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
KIT P10721 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25624103 0.90 AXL (0.69) AXLMERTKMETKDRAURKA
SCHEMBL30537442 0.88 AXL (0.69) AXLMERTKMETKDRAURKA
SCHEMBL22949662 0.88 AXL (0.69) AXLMERTKMETKDRAURKA
SCHEMBL22949533 0.88 AXL (0.81) AXLMERTKMETKDRAURKA
SCHEMBL21198863 0.88 AXL (0.67) AXLMERTKMETKDRAURKA
SCHEMBL22950612 0.87 AXL (0.68) AXLMERTKMETKDRAURKA
SCHEMBL22950481 0.84 AXL (0.72) AXLMERTKMETKDRAURKA
SCHEMBL28464572 0.83 AXL (0.76) AXLMERTKMETKDRAURKA
SCHEMBL30537418 0.83 AXL (0.70) AXLMERTKMETKDRAURKA
SCHEMBL22949536 0.83 AXL (0.70) AXLMERTKMETKDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936487-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-07-09 CN disclosed
CN-111936487-A Compounds for the treatment of kinase-dependent disorders 埃克塞里艾克西斯公司 2020-11-13 CN disclosed